FDA AI Medical Device Guidance: Safety & Evolving Software

The FDA's draft guidance for AI-enabled medical devices marks a big shift in how regulators approach software that changes over time. This framework recognizes AI's ability to evolve, while still focusing on patient safety, transparency, and accountability. What's interesting is that the non-binding guidance, released in 2025, requires manufacturers to address risks specific to AI systems. These include things like model drift, bias, and data poisoning. Instead of demanding static models, the FDA expects organizations to put in place predetermined change-control plans. These plans support monitoring, testing, and auditability. Phil Englert of Health-ISAC believes the FDA will finalize this guidance next year. He emphasizes the need for collaboration between manufacturers and healthcare providers. Organizations must have clear governance policies, approved AI tools, and staff education. This helps manage new risks and protects sensitive data. This guidance is important because it helps ensure the safety and reliability of evolving AI healthcare tools.